Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Good momentum in commercial CDMO business
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
The company reported lifetime high EBIDTA of Rs. 250 crores
Subscribe To Our Newsletter & Stay Updated
